Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Sorrento Therpt (SRNE)

7.93   1.03 (14.93%) 11-27 11:30
Open: 8.28 Pre. Close: 6.9
High: 8.3 Low: 7.6
Volume: 37,954,708 Market Cap: 2,085M
Sorrento Therapeutics, Inc., a clinical stage biopharma company, develops therapies for cancer, autoimmune, inflammatory, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches. It also offers Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. In addition, the company's clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases. Further, it develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. Additionally, the company engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. It has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; and Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection, as well as a research testing agreement with The University of Texas Medical Branch at Galveston for the preclinical testing of Sorrento's COVID-19 therapeutic product candidates. The company was founded in 2006 and is based in San Diego, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 7.233 - 7.277 7.277 - 7.319
Low: 6.484 - 6.532 6.532 - 6.578
Close: 6.824 - 6.897 6.897 - 6.967

Technical analysis

as of: 2020-11-27 11:19:05 AM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 9.69     One year: 11.32
Support: Support1: 6.37    Support2: 5.17
Resistance: Resistance1: 8.30    Resistance2: 9.69
Pivot: 6.80
Moving Average: MA(5): 7.31     MA(20): 6.88
MA(100): 8.89     MA(250): 5.67
MACD: MACD(12,26): -0.26     Signal(9): -0.47
Stochastic oscillator: %K(14,3): 71.98     %D(3): 70.64
RSI: RSI(14): 56.06
52-week: High: 19.39  Low: 1.55  Change(%): 136.8
Average Vol(K): 3-Month: 2149474  10-Days: 1531991

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
SRNE has closed above the upper band by 1.9%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 52.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to SRNE's normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Fri, 27 Nov 2020
DARPA and JPEO Award Contract to SmartPharm, a Subsidiary of Sorrento, for Development of Rapid Countermeasure Against COVID-19 Using Gene-Encoded Neutralizing Antibodies - Yahoo Finance

Fri, 20 Nov 2020
Sorrento Therapeutics on COVID-19 Therapy Competition: "Our Antibody Is Better Than Theirs" - The Motley Fool

Thu, 19 Nov 2020
How Will Sorrento Therapeutics Deal With the Added COVID-19 Competition? - Nasdaq

Tue, 17 Nov 2020
Unless Sorrento Makes Solid Progress Soon, It Will Likely Go Below $5 - InvestorPlace

Mon, 16 Nov 2020
Novavax and Sorrento Therapeutics: Are These Beaten-Down Coronavirus Stocks a Bargain? - Motley Fool

Sun, 15 Nov 2020
3 Ultra-Risky Robinhood Stocks That Just Might Make You a Fortune - Motley Fool

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 263
Shares Float (M) 199
% Held by Insiders 15.71
% Held by Institutions 27.41
Shares Short (K) 72,750
Shares Short P. Month (K) 75,730

Stock Financials

EPS -1.500
EPS Est This Year -1.070
EPS Est Next Year -0.650
Book Value (p.s.) 0.810
Profit Margin
Operating Margin -428.52
Return on Assets (ttm) -19.1
Return on Equity (ttm) -409.0
Qtrly Rev. Growth 103.4
Gross Profit (p.s.) -0.333
Sales Per Share 0.158
EBITDA (p.s.) -0.633
Qtrly Earnings Growth
Operating Cash Flow (M) -155
Levered Free Cash Flow (M) -141

Stock Valuations

PE Ratio -5.40
PEG Ratio
Price to Book value 10.00
Price to Sales 51.30
Price to Cash Flow -13.77

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.